The Technical Analyst
Accustem Sciences Inc. [ACUT]
Exchange: OTC Sector: Healthcare Industry: Biotechnology
Accustem Sciences Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
40.58% $0.388
America/New_York / 3 mai 2024 @ 14:38
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4.40 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | Mar 30, 2023 |
| SharesOutstanding: | 11.35 mill |
| Avg Daily Volume: | 0.0021 mill |
| RATING 2024-05-03 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 136.10 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0030 (-100.78%) $-0.391 |
| Date: 2024-05-05 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.320 - 0.456 ( +/- 17.53%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-12-30 | Cerrone Gabriele M | Buy | 5 000 | Common Stock |
| 2022-12-02 | Cerrone Gabriele M | Buy | 3 729 | Common Stock |
| 2022-11-18 | Cerrone Gabriele M | Buy | 24 500 | Common Stock |
| 2022-08-01 | Cerrone Gabriele M | Buy | 10 000 | Common Stock |
| 2022-06-08 | Cerrone Gabriele M | Buy | 20 000 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 6 transactions |
| Buy: 67 410 | Sell: 0 |
Forecast:
16:00 - $0.388
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.388 (40.58% ) |
| Volume | 0.0105 mill |
| Avg. Vol. | 0.0021 mill |
| % of Avg. Vol | 495.85 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ACUT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ACUT
AccuStem Sciences, Inc. operates as a life sciences company focusing on improving outcomes for patients with cancer. It develops StemPrintER technology, a multi-gene prognostic assay to predict the risk of recurrence of Endocrine receptor-positive /HER2- breast cancer; and Spare, a derivative of StemPrintER that combines StemPrintER with two clinical markers. The company is based in New York, New York.
Latest Press Releases
2023-07-15 02:12:38 - Press Release
Accustem Sciences, Inc. And Emeritusdx Announce Joint Product Development Agreement And Strategic Partnership
London and phoenix, july 17, 2023 (globe newswire) -- accustem sciences, inc. (otcqb: acut), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, and emeritusdx, a rapidly growing cancer diagnostics and information company, today announced the execution of an agreement wherein both companies will jointly manage scientific operations and r&d for accustem's product portfolio.
2023-07-11 07:00:00 - Press Release
Accustem Sciences, Inc. Extends And Broadens Partnership With Instituto Europeo Di Oncologia (ieo) Enabling Its Strategic Approach To Address Unanswered Clinical Questions In Early Stage Breast Cancer
London and phoenix, july 11, 2023 (globe newswire) -- accustem sciences, inc. (otcqb: acut), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, signs further agreement with the ieo, one of the most renowned comprehensive cancer centers in europe. this important milestone will support the company's strategic vision following positive results from transatac study where stemprinter assay outperformed the current market leader in risk of recurrence testing for women with early stage breast cancer.